Live Topical Biotherapeutics For The Treatment Inflammation And Itch

Effective | Fast Acting | Simple to Use
With an Unmatched Safety Profile

AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of Ammonia Oxidizing Bacteria (AOB), a critical part of the nitrogen cycle and by extension the immune system, whose presence as part of the human microbiome has been eliminated through modern living.

RESTORING IMMUNE FUNCTIONALITY

Ammonia Oxidizing Bacteria is involved in moderating immune response through the down-regulation of IL-4, IL-5, IL-13 and IL-31. Currently such inflammatory markers are targeted individually by on-market compounds and biologics. However, B244 targets those pathways simultaneously as ammonia oxidizing bacteria works as an extension of the immune system as opposed to a one off targeter of only certain cytokines. Such markers are associated with inappropriate inflammatory response in several diseases including atopic dermatitis and pruritus (itch) which is the basis for the science of our drug development program. In addition, these bacteria provide other benefits that include the production of skin metabolites which are pervasive throughout the cosmetic industry to help balance moisture and skin barrier functions, as well as down regulating bacterial populations that can lead to infections and other skin dysbiosis.

AOBiome currently has active Phase 3 and Phase 2 clinical programs

AOBiome currently has a Phase 3 clinical program in atopic dermatitis and Phase 2 clinical programs in acne, eczema and rosacea.

 

Learn More

Committed to transforming & improving human health

We believe re-populating these bacteria onto the skin is critical to maintaining a healthy immune system. Improper or aggressive immune response is the driver of numerous skin conditions, including effects such as excessive inflammation and itch.

 

In the News
USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244
AOB Pharma featured in ‘Genetic Engineering & Biotechnology News’
AOBiome and Maruho have entered into an Exclusive License Agreement for a Novel Therapeutic for the treatment of Atopic Dermatitis in Japan